NOVN.CH

96.14

+1.25%↑

SOON.CH

239.4

-0.95%↓

NOVN.CH

96.14

+1.25%↑

SOON.CH

239.4

-0.95%↓

NOVN.CH

96.14

+1.25%↑

SOON.CH

239.4

-0.95%↓

NOVN.CH

96.14

+1.25%↑

SOON.CH

239.4

-0.95%↓

NOVN.CH

96.14

+1.25%↑

SOON.CH

239.4

-0.95%↓

Search

Roche Holding AG

Closed

SectorHealthcare

278 1.09

Overview

Share price change

24h

Current

Min

275

Max

279.2

Key metrics

By Trading Economics

Income

-4.2B

2B

Sales

-109M

31B

P/E

Sector Avg

26.874

50.291

Dividend yield

3.5

Profit margin

6.588

Employees

103,249

EBITDA

-4.6B

6B

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.50%

2.40%

Market Stats

By TradingEconomics

Market Cap

-11B

208B

Previous open

276.91

Previous close

278

News Sentiment

By Acuity

22%

78%

45 / 380 Healthcare

Roche Holding AG Chart

Past performance is not a reliable indicator of future results.

Related News

11 Jun 2025, 08:25 UTC

Acquisitions, Mergers, Takeovers

EQT, Sanofi Co-Led $135 Million Funding Round for Spanish Biotech Company SpliceBio

12 May 2025, 02:16 UTC

Major Market Movers

Asia Pharma Stocks Fall After Trump's Plan to Cut Drug Costs

24 Apr 2025, 07:30 UTC

Earnings

Roche Sales Gain on Boost From Key Drugs Amid U.S. Production Push -- Update

24 Apr 2025, 05:31 UTC

Earnings

Roche Sales Rise Boosted By Key Drugs

9 Apr 2025, 09:39 UTC

Major Market Movers

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

12 Mar 2025, 09:23 UTC

Major Market Movers

Zealand Pharma Shares Leap After Weight-Loss Licensing Deal With Roche

30 Jan 2025, 09:36 UTC

Earnings

Roche Expects Growth to Continue This Year After Sales, Earnings Beat Forecasts -- Update

30 Jan 2025, 06:32 UTC

Earnings

Roche Expects Sales, Earnings Growth After Better-Than-Expected Results

16 Jun 2025, 08:55 UTC

Hot Stocks

Stocks to Watch: Victoria's Secret, Renault, U.S. Steel, Sarepta -- WSJ

3 Jun 2025, 07:51 UTC

Market Talk

Roche Unlikely to Get Revenue Boost From Tecentriq Combination With Lurbinectedin -- Market Talk

21 May 2025, 07:20 UTC

Market Talk

Roche Lymphoma Drug Columvi Dealt Setback by FDA Committee -- Market Talk

2 May 2025, 06:25 UTC

Market Talk
Earnings

Roche Shows Pipeline Progress But Near-Term Risks Remain -- Market Talk

24 Apr 2025, 09:39 UTC

Market Talk
Earnings

Roche's Pipeline in Focus After Solid Results -- Market Talk

24 Apr 2025, 09:24 UTC

Market Talk
Earnings

Roche's Reiterated Outlook Looks Reassuring -- Market Talk

24 Apr 2025, 09:18 UTC

Market Talk
Earnings

Roche's Results Are Solid -- Market Talk

24 Apr 2025, 05:16 UTC

Top News

Roche Sales Rise, Boosted By Key Drugs

22 Apr 2025, 10:51 UTC

Top News

Drug Companies Step Up 'Make in America' Plans to Counter Tariffs -- WSJ

15 Apr 2025, 09:55 UTC

Market Talk

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

9 Apr 2025, 10:03 UTC

Market Talk
Earnings

Roche's Eye Drug in Focus for 1Q Earnings -- Market Talk

9 Apr 2025, 07:23 UTC

Market Talk

Pharma Stocks Tumble After Trump Floats Tariffs on Industry -- Market Talk

3 Apr 2025, 08:41 UTC

Market Talk

Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk

3 Apr 2025, 07:51 UTC

Market Talk

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

31 Mar 2025, 09:31 UTC

Hot Stocks

Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ

13 Mar 2025, 07:46 UTC

Market Talk

Roche's Zealand Pharma Deal Signals Commitment to Obesity Drug Market -- Market Talk

12 Mar 2025, 16:34 UTC

Top News

Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal -- Update

12 Mar 2025, 08:51 UTC

Market Talk

Roche's Multiple-Sclerosis Drug Sales Potential Fuels Rating Upgrade -- Market Talk

12 Mar 2025, 08:18 UTC

Market Talk

Roche's Obesity Deal With Zealand Pharma Makes Sense, Vontobel Says -- Market Talk

13 Feb 2025, 11:43 UTC

Market Talk

Roche's Growth Fueled by Key Drugs, Promising Pipeline -- Market Talk

30 Jan 2025, 07:56 UTC

Market Talk
Earnings

Roche Delivered Solid Results But Diagnostics' Profitability Disappoints -- Market Talk

30 Jan 2025, 06:04 UTC

Earnings

Roche Expects 2025 EPS Growth in High Single Digit Range at Constant Currency

Peer Comparison

Price change

Roche Holding AG Forecast

Sentiment

By Acuity

45 / 380 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.